The U.S. doesn’t have an official job code for clinical research professionals. David Vulcano explains why that gap is holding back the workforce.
- The Data Was Already There: RWE's Real Bottleneck Is People
- Two Planning Mistakes That Quietly Sink Clinical Programs
- Duplicate Tech, Not Technology, Is Burning Out Trial Sites
- The Real Reason Clinical Trial Systems Don't Talk To Each Other
- The Vendor Questions Most Clinical Tech Buyers Forget To Ask
- AI In Clinical Trials: Stop Hyping It, Start Proving It
- What AI Can't Fix In Decentralized Clinical Trial Data
- Decentralized Trials Promised Less Burden. Did They Deliver?
ON-DEMAND WEBINARS
Learn how AI-enabled eCOA can reduce complexity in trial setup by cutting unnecessary meetings, speeding execution, and helping teams focus on what matters most.
During this webinar, speakers will discuss how they are successfully deploying wearable and remote monitoring technologies to improve clinical outcomes in patients living with cancer.
This presentation delves into pragmatic approaches for clinical evidence generation and regulatory acceptance. It examines recent FDA draft guidance on integrating RWD/RWE in medical device studies.
Watch to learn how you can build a better data management and compliance monitoring plan for your COAs in your next DCT trial.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1416816620 medical records, RWE]( "Europe Has A Platform For Driving More Flexible Clinical Trials")
Europe Has A Platform For Driving More Flexible Clinical TrialsDespite recent setbacks, Europe possesses inherent strengths in clinical research, and a concerted effort is needed to transform its potential into a thriving and competitive environment.
-
![ERI Quiz Looking At Computer Desk]( "Reduce Workloads And Improve Insights With Crowdsource UAT")
Reduce Workloads And Improve Insights With Crowdsource UATLearn to expedite UAT through objective evidence exchange, decreased individual workloads for participating sponsors, increased access to users, and faster, more reliable testing.
-
![Ispor CEO]( "Hope In The Dark: Value In Alzheimer's Disease Research And Treatment")
Hope In The Dark: Value In Alzheimer's Disease Research And TreatmentThe May/June 2025 issue of Value & Outcomes Spotlight explores the health economics and outcomes research (HEOR) and its contribution to research and treatment of Alzheimer’s disease.
-
![GettyImages-1133924836 software]( "How SaaS Unlocks New Possibilities For Life Science Organizations")
How SaaS Unlocks New Possibilities For Life Science OrganizationsThe rise of SaaS (software-as-a-service) has transformed industries, including life sciences, by enabling new possibilities. See how it’s already helping life science organizations around the world today.
-
![GettyImages-1648451225 Scientist holding tray of samples in laboratory]( "Introducing Digitally-Enabled Biosample Consent Storage")
Introducing Digitally-Enabled Biosample Consent StorageDespite the rise of digital solutions in healthcare, paper consent forms are still common in today’s clinical trials. Unfortunately, these paper forms pose significant challenges in retaining the documentation of informed consent for centrally stored biospecimens.
-
![Pharma bioprocess quality GettyImages-1138461306]( "Three Ways That eCOA Improves Data Quality")
Three Ways That eCOA Improves Data QualityFollow this quick guide to the key ways that eCOA works to help all study stakeholders (patients, caregivers, study teams, etc.) produce better data.
-
![Data Electronics]( "Discover The Value Your eTMF Should Deliver")
Discover The Value Your eTMF Should DeliverA well-prepared Trial Master File (TMF) is critical to the success of any clinical trial. Because the TMF tells the whole story of a study – including every data point collected and decision made – managing it throughout the course of the trial is challenging.
-
![Poor Protocol Design Is Costing You More Than Money]( "Why Amendments Break Trials and How Elosity R3 Fixes It")
Why Amendments Break Trials and How Elosity R3 Fixes ItProtocol amendments are inevitable. The challenge is managing them without disrupting trial execution.
-
![GettyImages-645455610 doctor, liver]( "Supporting NASH/NAFLD's Unmet Needs With ePRO")
Supporting NASH/NAFLD's Unmet Needs With ePROExplore the rising prevalence of NASH/MASH, its debilitating effects, and the urgent need for patient-centric approaches in clinical research.
-
![GettyImages-1356381571 world data]( "Using RWE To Get To Insights And Action — Faster")
Using RWE To Get To Insights And Action — FasterDelve into three examples that vividly showcase the formidable power of real-world evidence from the early stages of drug development through clinical trials and commercialization.
- Clinical Research Isn't Even A Recognized Job. That's A Problem.
- The Data Was Already There: RWE's Real Bottleneck Is People
- Two Planning Mistakes That Quietly Sink Clinical Programs
- Duplicate Tech, Not Technology, Is Burning Out Trial Sites
- The Real Reason Clinical Trial Systems Don't Talk To Each Other
RECENT NEWSLETTERS
- 09.10.26 -- AI, Trial Costs, And RTSM Are Reshaping Clinical Operations
- 09.05.26 -- Best Of August: AI, FDA RWE, And Trial Data Risks
- 09.03.26 -- AI, APIs, and eConsent Are Exposing Trial Workflow Gaps
- 08.27.26 -- Patient Data Breaks Down When Trial Systems Miss Reality
- 08.20.26 -- Clinical AI Validation, Trial Handoffs, And Smarter Study Builds
